{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:34:20Z","timestamp":1775234060881,"version":"3.50.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.cmi.2020.04.031","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T21:49:55Z","timestamp":1588196995000},"page":"880-894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)"],"prefix":"10.1016","volume":"26","author":[{"given":"M.","family":"Bassetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.R.","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Barisione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Centanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.G.","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Granata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Petrosillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Richeldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Santus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Viale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2020.04.031_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13209","article-title":"The novel Chinese coronavirus (2019-nCoV) infections: challenges for fighting the storm","volume":"50","author":"Bassetti","year":"2020","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cmi.2020.04.031_bib2","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.11.2000285","article-title":"Rapidly increasing cumulative incidence of coronavirus disease (COVID-19) in the European union\/European economic area and the United Kingdom, 1 january to 15 March 2020","author":"Kinross","year":"2020","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2020.04.031_bib3","doi-asserted-by":"crossref","DOI":"10.3201\/eid2607.200359","article-title":"Early introduction of severe acute respiratory syndrome coronavirus 2 into Europe","author":"Olsen","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30195-X","article-title":"Real estimates of mortality following COVID-19 infection","author":"Baud","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib5","series-title":"Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship","author":"Mizumoto","year":"2020"},{"key":"10.1016\/j.cmi.2020.04.031_bib6","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(20)30627-9","article-title":"COVID-19 and Italy: what next?","volume":"395","author":"Remuzzi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.04.031_bib7","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1016\/S2214-109X(20)30074-7","article-title":"Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts","volume":"8","author":"Hellewell","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.cmi.2020.04.031_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2020.04.031_bib9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2020.04.031_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-020-06022-5","article-title":"Surviving Sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)","author":"Alhazzani","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib12","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMoa1503326","article-title":"High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure","volume":"372","author":"Frat","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib13","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.rmed.2009.04.007","article-title":"Research in high flow therapy: mechanisms of action","volume":"103","author":"Dysart","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib14","doi-asserted-by":"crossref","first-page":"1602426","DOI":"10.1183\/13993003.02426-2016","article-title":"Official ERS\/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure","volume":"50","author":"Rochwerg","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2020.04.031_bib15","series-title":"Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected","author":"World Health Organization (WHO)","year":"2020"},{"key":"10.1016\/j.cmi.2020.04.031_bib16","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2213-2600(20)30084-9","article-title":"Staff safety during emergency airway management for COVID-19 in Hong Kong","volume":"8","author":"Cheung","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib17","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202003-0817LE","article-title":"COVID-19 does not lead to a \u2018typical\u2019 acute respiratory distress syndrome","author":"Gattinoni","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib18","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa1214103","article-title":"Prone positioning in severe acute respiratory distress syndrome","volume":"368","author":"Guerin","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib19","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1093\/jac\/dkw338","article-title":"A\u00a0review of treatment modalities for Middle East respiratory syndrome","volume":"71","author":"Mo","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.04.031_bib20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses","volume":"14","author":"de Wit","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2020.04.031_bib21","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib22","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A\u00a0trial of lopinavir\u2013ritonavir in adults hospitalized with severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in\u00a0vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.cmi.2020.04.031_bib24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2020.04.031_bib25","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2020.04.031_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2020.04.031_bib27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3201\/eid1004.030458","article-title":"Inhibition of SARS coronavirus infection in\u00a0vitro with clinically approved antiviral drugs","volume":"10","author":"Tan","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.04.031_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.cmi.2020.04.031_bib30","article-title":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial","volume":"2020","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.04.031_bib31","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in\u00a0vitro","author":"Caly","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.cmi.2020.04.031_bib32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","article-title":"In\u00a0vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine","volume":"323","author":"Keyaerts","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cmi.2020.04.031_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In\u00a0vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2020.04.031_bib35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41565-020-0674-9","article-title":"Insights from nanomedicine into chloroquine efficacy against COVID-19","volume":"15","author":"Hu","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.cmi.2020.04.031_bib36","first-page":"55","article-title":"Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells","volume":"24","author":"van den Borne","year":"1997","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cmi.2020.04.031_bib37","article-title":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression","author":"Zhou","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2020.04.031_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa321","article-title":"Could chloroquine\/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment?","author":"Guastalegname","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib39","doi-asserted-by":"crossref","first-page":"105945","DOI":"10.1016\/j.ijantimicag.2020.105945","article-title":"Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine","volume":"55","author":"Sahraei","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2020.04.031_bib40","article-title":"A\u00a0systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","author":"Cortegiani","year":"2020","journal-title":"J\u00a0Crit Care"},{"key":"10.1016\/j.cmi.2020.04.031_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2020.04.031_bib42","doi-asserted-by":"crossref","DOI":"10.7326\/M20-1223","article-title":"A\u00a0rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19","author":"Kim","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","author":"Molina","year":"2020","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.cmi.2020.04.031_bib44","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.04.031_bib45","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib46","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib48","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib49","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/j.ijid.2012.01.003","article-title":"Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza","volume":"16","author":"Metersky","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2353\/ajpath.2010.100115","article-title":"2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States","volume":"177","author":"Shieh","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cmi.2020.04.031_bib51","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3201\/eid1206.051141","article-title":"Severe community-acquired pneumonia due to Staphylococcus aureus, 2003\u201304 influenza season","volume":"12","author":"Hageman","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib52","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/infdis\/jir861","article-title":"Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection","volume":"205","author":"Paddock","year":"2012","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib53","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1086\/652291","article-title":"Invasive group A streptococcal infection concurrent with 2009 H1N1 influenza","volume":"50","author":"Jean","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib54","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","article-title":"On the use of corticosteroids for 2019-nCoV pneumonia","volume":"395","author":"Shang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.04.031_bib55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.04.031_bib56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcv.2004.07.006","article-title":"Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients","volume":"31","author":"Lee","year":"2004","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.cmi.2020.04.031_bib57","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib58","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/j.lpm.2011.04.023","article-title":"Pathophysiology of acute respiratory distress syndrome. Glucocorticoid receptor\u2013mediated regulation of inflammation and response to prolonged glucocorticoid treatment","volume":"40","author":"Umberto Meduri","year":"2011","journal-title":"Presse Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib59","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1378\/chest.108.5.1315","article-title":"Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS","volume":"108","author":"Gu","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2020.04.031_bib60","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1164\/ajrccm.165.7.2106014","volume":"165","author":"Gu","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib61","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/CCM.0b013e318232da5e","article-title":"Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome","volume":"40","author":"Seam","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib62","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1097\/CCM.0b013e31819fb507","article-title":"Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis","volume":"37","author":"Tang","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib63","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib64","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1378\/chest.129.6.1441","article-title":"Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience","volume":"129","author":"Chen","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2020.04.031_bib65","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome","volume":"197","author":"Arabi","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13054-019-2395-8","article-title":"The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis","volume":"23","author":"Ni","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2020.04.031_bib67","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.04.031_bib68","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib69","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.04.031_bib70","article-title":"Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.04.031_bib71","author":"Xu"},{"key":"10.1016\/j.cmi.2020.04.031_bib72","year":"2020"},{"key":"10.1016\/j.cmi.2020.04.031_bib73","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.04.031_bib74","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cmi.2020.04.031_bib75","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4940","article-title":"Convalescent plasma to treat COVID-19: possibilities and challenges","author":"Roback","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2020.04.031_bib76","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2020.04.031_bib77","doi-asserted-by":"crossref","first-page":"ofaa102","DOI":"10.1093\/ofid\/ofaa102","article-title":"High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease, 2019","volume":"7","author":"Cao","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib78","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13054-020-2818-6","article-title":"Treatment of COVID-19: old tricks for new challenges","volume":"24","author":"Cunningham","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2020.04.031_bib79","first-page":"399","article-title":"Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study","volume":"9","author":"Chan","year":"2003","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.cmi.2020.04.031_bib80","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/cid\/ciy860","article-title":"Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes","volume":"69","author":"Katzen","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib81","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/cid\/cis636","article-title":"Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09","volume":"55","author":"Louie","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib82","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2020.04.031_bib84","first-page":"185","volume":"43","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1016\/j.cmi.2020.04.031_bib85","doi-asserted-by":"crossref","DOI":"10.4081\/idr.2020.8543","article-title":"Recommendations for COVID-19 clinical management","author":"Nicastri","year":"2020","journal-title":"Infect Dis Rep"},{"key":"10.1016\/j.cmi.2020.04.031_bib86","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/infdis\/jix536","article-title":"Drug development for multidrug-resistant bacteria: why compromise?","volume":"217","author":"Paul","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2020.04.031_bib87","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/17512433.2019.1680283","article-title":"A\u00a0look at clinical trial design for new antimicrobials for the adult population","volume":"12","author":"Bassetti","year":"2019","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20302573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20302573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:25:46Z","timestamp":1761117946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X20302573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":86,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1198743X20302573"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2020.04.031","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2020.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}